 Karen Zaderej-Chief Executive Officer
Karen Zaderej has over 20 years of experience in the medical device market. At Johnson & Johnson, she held senior positions in marketing, business development, R&D and ran a manufacturing business. After leaving J&J, she founded Zaderej Medical Consulting to assist medical device companies build and execute winning commercialization plans. She has an MBA from the Kellogg Graduate School of Business and a BS in Chemical Engineering from Purdue University.
|
 John P. Engels-Vice President, Co-Founder
John Engels provides operational and financial leadership for AxoGen, managing the company’s strategic and product development partnerships. He has extensive experience in life-science entrepreneurship and early-stage finance, most recently working with the University of Florida and with PA Early Stage Partners, a venture capital fund in Philadelphia. John worked for several years in the boutique investment banking firm CACM, pioneering a multi-billion dollar emissions trading market and helping to launch Power Navigator, a high-speed electricity transmission exchange. John holds an MBA in Management and Operations from the Wharton School of Business at the University of Pennsylvania, and a BA from the University of Chicago.
|
 Erick DeVinney- Director of Clinical Research
Erick DeVinney has over eight years of experience in the successful planning and management of clinical trials. He has a diverse background including research at a large academic facility and management of clinical operations for a medical device company. Erick has been involved in clinical research at Medical College of Virginia Hospitals, National Clinical Research, PRA International, and Angiotech. He has been involved in the successful submission of eight IDE or NDA applications as well as numerous 510(k)s. He has a B.S. in Chemistry from Virginia Commonwealth University.
|
 Marlo Tan Walpole-Director of Biotechnology Development
Marlo Tan Walpole has several years of experience successfully managing various aspects of Product Development in the allograft, medical device and biologic industries. She has worked for US Biomaterials (now known as Nova Bone Products LLC and NovaMin Technology Inc.), Regeneration Technologies (now known as RTI Biologics), and Ixion Biotechnology (technology now owned by OxThera Therapeutics) in areas of increasing responsibility including managing a cross-functional team in clinical trial production. She has also managed several biomaterials projects from research to production and helped actively market several products. Marlo has been with AxoGen since 2003 and has focused her efforts on identifying leading researchers and clinicians in the field of peripheral nerve treatment and on the development of products specifically geared for peripheral nerve repair. Marlo has an MS in Biomedical Engineering and BS in Biology.
|
 Jerry Chang-Director of Product Development and Operations
Jerry Chang is a highly skilled operations executive with over 15 years of extensive leadership experience in the medical device, allograft, and pharmaceutical industries. In his current executive capacities with AxoGen Inc., Jerry oversees operations, customer service and product development and is responsible for overall management, operation, and maintenance of on and offsite locations to ensure and maintain compliance with state, federal and international regulations. Through his tenure with the company, he has managed the research, development and successful launch of three peripheral nerve products. In his previous roles, Jerry worked for Regeneration Technologies, Inc. (now known as RTI Biologics), Abbott Laboratories, and Fuji Hunt Chemical Corporation in areas of increasing responsibility including quality oversight and technical validity of a 400 person biotechnology company and its wholly owned subsidiaries. Jerry has also managed several successful biotechnology projects from research to production including the design, development, and integration of a chemical sterilization system that permits, for the first time, GMP compliant sterile formulation of biological tissue implants. He has also been involved with multiple successful 510(k) and CE Mark submissions. He has a BS in Biology from Illinois Wesleyan University.
|
